Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy.

PURPOSE To evaluate dosimetric factors predictive for radiation-induced pneumonitis (RP) after pulmonary stereotactic body radiotherapy (SBRT). MATERIALS AND METHODS A retrospective analysis was performed based on 59 consecutive patients treated with cone-beam CT-based image-guided SBRT for primary NSCLC (n=21) or pulmonary metastases (n=54). The majority of patients were treated with radiosurgery of 26 Gy to 80% (n=29) or three fractions of 12.5 Gy to 65% (n=40). To correct for different single fraction doses, local doses were converted to 2 Gy equivalent normalized total doses (NTDs) using α/β ratio of 3 Gy for RP. Dose-volume parameters and incidences of RP ≥ grade II SWOG were fitted using NTCP models. RESULTS Eleven patients developed RP grade II. With an average MLD of 10.3±5.6 Gy to the ipsilateral lung, a significant dose-response relationship was observed: the MLD was 12.5±4.3 Gy and 9.9±5.8 Gy for patients with and without development of RP, respectively. Additionally, volumes of the lung exposed to minimum doses between 2.5 and 50 Gy (V(2.5)-V(50)) were correlated with incidences of RP with a continuous decrease of the goodness of fit for higher doses. CONCLUSIONS The MLD and V(2.5)-V(50) of the ipsilateral lung were correlated with incidences of RP after pulmonary SBRT.

[1]  G. Glatting,et al.  Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test. , 2007, Medical physics.

[2]  Joos V Lebesque,et al.  Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. , 2003, International journal of radiation oncology, biology, physics.

[3]  C. Ling,et al.  Results of a phase I dose‐escalation study using three‐dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma , 2005, Cancer.

[4]  K. Forster,et al.  The relationship between local dose and loss of function for irradiated lung. , 2003, International journal of radiation oncology, biology, physics.

[5]  Joe Y. Chang,et al.  Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.

[6]  R K Ten Haken,et al.  Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. , 1998, International journal of radiation oncology, biology, physics.

[7]  K. Ohtomo,et al.  Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors , 2007, Radiation oncology.

[8]  Matthias Guckenberger,et al.  Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  J A Purdy,et al.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.

[10]  Zhongxing Liao,et al.  Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). , 2005, International journal of radiation oncology, biology, physics.

[11]  W. Schlegel,et al.  Prediction of radiation-induced changes in the lung after stereotactic body radiation therapy of non-small-cell lung cancer. , 2007, International journal of radiation oncology, biology, physics.

[12]  Matthias Guckenberger,et al.  Cone-beam CT based image-guidance for extracranial stereotactic radiotherapy of intrapulmonary tumors , 2006, Acta oncologica.

[13]  Matthias Guckenberger,et al.  Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. , 2009, International journal of radiation oncology, biology, physics.

[14]  J. Lebesque,et al.  Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. , 2006, International journal of radiation oncology, biology, physics.

[15]  J. Lebesque,et al.  The simultaneous boost technique: the concept of relative normalized total dose. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  A. Agresti,et al.  Approximate is Better than “Exact” for Interval Estimation of Binomial Proportions , 1998 .

[17]  E. Smit,et al.  Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.

[18]  Y. Onodera,et al.  Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[19]  X Allen Li,et al.  Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. , 2004, Physics in medicine and biology.

[20]  S. Moolgavkar,et al.  A Method for Computing Profile-Likelihood- Based Confidence Intervals , 1988 .

[21]  M. Flentje,et al.  A Little to a Lot or a Lot to a Little? , 2003, Strahlentherapie und Onkologie.

[22]  Jan-Jakob Sonke,et al.  Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  Lawrence B Marks,et al.  The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. , 2008, Seminars in radiation oncology.

[24]  J. Bedford,et al.  Review of hypofractionated small volume radiotherapy for early-stage non-small cell lung cancer. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[25]  Hiroki Shirato,et al.  STEREOTACTIC RADIATION THERAPY WORKSHOP Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional Study , 2007 .

[26]  David Pérol,et al.  A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  Matthias Guckenberger,et al.  Intra-fractional uncertainties in cone-beam CT based image-guided radiotherapy (IGRT) of pulmonary tumors. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  E. Smit,et al.  Stereotactic radiotherapy for centrally located early-stage lung tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Andrew Jackson,et al.  Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. , 2004, International journal of radiation oncology, biology, physics.

[30]  Seong Soo Shin,et al.  Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. , 2009, Lung cancer.

[31]  T. Kimura,et al.  CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers? , 2006, International journal of radiation oncology, biology, physics.

[32]  S. Kuribayashi,et al.  Radiation injury after hypofractionated stereotactic radiotherapy for peripheral small lung tumors: serial changes on CT. , 2004, AJR. American journal of roentgenology.

[33]  Lech Papiez,et al.  Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  José Belderbos,et al.  Biology contributionComparing different NTCP models that predict the incidence of radiation pneumonitis , 2003 .

[35]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[36]  Jeffrey Bradley,et al.  Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. , 2005, International journal of radiation oncology, biology, physics.

[37]  M. Hiraoka,et al.  Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance. , 2004, Radiology.